Andhra Pradesh to introduce advanced breast cancer screening

In Short

BPCL to provide 750 iBreast devices worth Rs 56 crore

Health minister Y Satya Kumar Yadav reviews the use of iBreast devices with trained women community health officers and officials at Mangalagiri on Friday
X

Health minister Y Satya Kumar Yadav reviews the use of iBreast devices with trained women community health officers and officials at Mangalagiri on Friday

Font size
FOLLOW ON Google News

Amaravati: Andhra Pradesh is set to introduce advanced sensor-based technology for early detection of breast cancer, with plans to screen lakhs of women across the state using iBreast Exam (iBE) devices during the upcoming Non-Communicable Diseases (NCD) screening programme.

Health minister Y Satya Kumar Yadav announced that the Health Department was making arrangements to conduct breast examinations at the village level, either at women’s homes or Village Health Clinics. The initiative is expected to make Andhra Pradesh the first state in the country to undertake large-scale breast screening using this technology.

The minister reviewed the utilisation of iBreast devices with trained women community health officers and officials, discussing precautions, training and implementation strategies. He said Chief Minister N. Chandrababu Naidu was giving priority to technology-driven healthcare. The state had already received international recognition for introducing AI-based medical services through the MedTech Challenge.

Developed by UE LifeSciences, the portable, battery-operated iBreast device uses Dynamic Co-Planar Capacitive Sensor technology to identify abnormal tissue changes. It provides colour-coded digital results on a mobile device immediately after the examination. Each test takes approximately 20 minutes and involves no radiation, compression or invasive procedures.

Officials clarified that the device is a screening aid and not a substitute for definitive cancer diagnosis. Women showing abnormalities will be referred to PHCs, district hospitals and medical colleges for further investigations, including ultrasound, mammography and biopsy, wherever necessary.

The device has received USFDA and CDSCO approvals. Studies, including one conducted at AIIMS Rishikesh, have reported screening accuracy of around 86 per cent. A committee led by renowned oncologist Dr Nori Dattatreyudu has also approved its implementation.

Under its corporate social responsibility initiative, Bharat Petroleum Corporation Limited (BPCL) has agreed to provide 750 devices worth approximately Rs 56 crore, costing around Rs 7.5 lakh each. HLL Infratech Services Limited (HITES) is procuring them. The first 375 devices have already been distributed across 13 districts, with the remaining units to follow. The programme is expected to benefit 8–10 lakh women.

The Hans India
ABOUT THE AUTHOR

The Hans India

Next Story
Share it